- The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library
- The DDF and Aptuit enter into a strategic partnership to leverage the DDF library and Aptuit’s capabilities for dementia drug discovery
London, Boston, Greenwich - February 28, 2017 – The Dementia Discovery Fund (‘DDF’), a venture capital fund focused on discovering and developing novel therapies for dementia, and Aptuit, an integrated drug discovery CRO, announce a strategic drug discovery partnership to kick-start small molecule drug discovery programmes for novel dementia-related targets. 
The DDF has acquired a 513,000 compound, CNS-focussed small molecule library. Together with Aptuit, the DDF, DDF companies, partners and collaborators will be able to run high throughput screens using this curated library, biased towards compound properties favourable for CNS drug discovery.
The combination of DDF’s CNS discovery expertise and 
Aptuit’s world-class drug discovery capabilities will support companies and academics to translate their biological, genetic and other insights into successful drug discovery programmes, cultivating acceleration of innovation in the dementia field.
Read full press release from the Dementia Discovery Fund site